Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New Drug Sponsors Should Not Contact US FDA Reviewers Directly, Draft Guidance Asserts

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration is urging investigational new drug application sponsors to communicate directly with review division regulatory project managers instead of contacting project managers and reviewers.